Drug companies have freedom under the Food and Drug Administration rules to ignore their rival's patents when starting research on competing medications, the Supreme Court ruled Monday. The unanimous decision means that big drug companies will have more flexibility to start experimenting with potential therapies so long as they cannot feasibly be marketed until after a competitor's patent expires. Lower courts will have to sort out just how much leeway the companies will have.
June 14, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Drug companies have freedom under the Food and Drug Administration rules to ignore their rival’s patents when starting research on competing medications, the Supreme Court ruled Monday.
The unanimous decision sets aside a lower court ruling for patent holder Integra LifeSciences Holdings Corp.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
A prominent AV-rated Education Law firm seeks an associate with 5+ years experience. The role will primarily involve advice and counsel in ...
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
